Ropes & Gray advised Genesis Therapeutics in a in a strategic collaboration with Gilead Sciences to discover and develop novel small molecule therapies across multiple targets. The collaboration will use the advanced AI technologies of Genesis to generate therapeutic candidates for targets selected by Gilead. The deal was announced on September 10.
Under the agreement, Genesis will receive an upfront cash payment of $35 million across three targets and Gilead will have an option to nominate additional targets for a predetermined per-target fee. The collaboration will focus on preclinical research, with Gilead holding sole rights for potential clinical development and commercialization of collaboration compounds.
The Ropes & Gray team included life sciences licensing partner Marc Rubenstein, IP transactions counsel Joshua Jackson and IP transactions associate Atiyah Wang.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.